Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Kyverna Therapeutics, Inc.

NASDAQ: KYTX · Life Sciences · 3 alerts · CIK 1994702

Share price
$4.76Close, Nov 16
Market cap
$301M
Shares outstanding
63.22MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Kyverna Therapeutics, Inc. filings on SEC EDGAR ↗

8:05 AM ET 10-Q
Financial Results

Kyverna Therapeutics Q3 2026 Results: Net Loss of $41.9M, Loss Widens

Kyverna Therapeutics reported a net loss of $119.99 million for the nine months ended September 30, 2026, compared to $123.50 million in the prior year period. The company's cash and marketable securities position decreased to $170.57 million as of September 30, 2026, down from $279.25 million at the end of 2025, primarily due to ongoing research and development expenses.

Key figure
Net loss $41.9M
8:02 AM ET 8-K
Financial Results

Kyverna Therapeutics Financial Results

Kyverna Therapeutics reported Q3 2026 financial results and announced the completion of its rolling BLA submission to the FDA for miv-cel in Stiff Person Syndrome (SPS). The company ended the quarter with $312.4 million in cash and equivalents, which it expects will fund operations into 2028 as it prepares for a potential commercial launch in 2027.

Term
Q3 2026

“Kyverna is very proud to submit the first BLA for a CAR T-cell therapy in autoimmune disease, paving the way for a potential new standard of care with a single dose, designed to reset the immune system and free patients from lifelong disease and chronic immunotherapies.”

Warner Biddle, Chief Executive Officer of Kyverna
6:02 AM ET 8-K
Clinical Trial Data

Kyverna Therapeutics Clinical Trial Data

Kyverna Therapeutics announced positive one-year topline data from its KYSA-8 registrational trial for miv-cel in stiff person syndrome (SPS) and longer-term follow-up data from its KYSA-6 trial in generalized myasthenia gravis (gMG). The results demonstrated durable clinical responses and a favorable safety profile, supporting the company's plan to complete a rolling BLA submission for SPS in Q4 2026.

Earnings call
Sep 29, 2026, 10:15 AM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.